For our investors

Introducing Spermosens

Developer of revolutionizing medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments. Spermosens is listed on Spotlight Stock Market since 5th of May 2021.

The World Health Organization has identified infertility as a global health issue, affecting approximately 15 percent of the global population in the fertile age group. This is equal to around 60 million couples, being impacted by infertility. In half of the cases, the cause of infertility is the male factor. Spermosens is developing a revolutionizing technology for male fertility diagnostics and fertility treatment.

With Spermosens first product, JUNO- Checked, it will – for the first time – be possible to determine a sperms ability to fertilize the egg cell. This in turn enables the IVF clinic to choose the appropriate fertilization treatment. Today, around 85 percent of IVF treatments fail. Being able to determine the sperm’s ability to fertilize the egg cell is expected to cause to a reduction in the number of IVF-treatments. This leads to:

Reduced waiting period for childless couples
Less negative phycological effects
Reduced cost for the couples in treatment
Reduced need for hormonal treatments of the female
Increased capacity of each IVF clinic
Improved financial outlook for IVF clinics

”We estimate the global sales potential to be around five billion SEK per year, assuming that all of the 3,600 clinics, which we have identified as potential clients, make use of JUNO-Checked for all of their IVF treatments. We won’t be able to reach the entirety of the global market at once, but with our unique product offering and competitive edge, I predict that we will be able to capture a very high market share”.

John Lempert, CEO

The Share

Spermosens AB (publ) is listed on Spotlight Stockmarket. The share is traded under the ticker SPERM and ISIN-code SE0015346424.

Spotlight is an alternative market and does not have the same legal status as regulated market. Companies at Spotlight Stockmarket are subject to the rules of Spotlight and not the legal requirements for admission to trading on a regulated market. An investment in a company that is traded on Spotlight Stockmarket is riskier than an investment in a company that is traded on a regulated market.

The Technology

Learn more

For our investors

Introducing Spermosens

The Share

Spermosens AB

Legal notices